
via Genetic Engineering & Biotechnology News
In pre-clinical testing, traditionally injected drugs such as insulin, epinephrine, GLP-1 receptor agonists and monoclonal antibodies were orally delivered with comparable results
Many people suffering from diseases like Crohn’s disease, rheumatoid arthritis, and diabetes inject themselves or have to receive drug infusions to help treat their disease. These injections require training, equipment and often take a toll on one’s life. But what if you could take monoclonal antibodies, insulin and other injectables as a pill? A study by investigators at Brigham and Women’s Hospital, Massachusetts Institute of Technology and Novo Nordisk unveils a new type of self-injecting capsule, called the liquid-injecting self-orienting millimeter-scale applicator (L-SOMA) that administers typically injected liquid medications orally. In large animal preclinical models, investigators used this technology to deliver four commonly injected medications, including a monoclonal antibody. Findings are published in Nature Biotechnology.
“We recognize today that pills are the preferred route of drug administration, not only for patients, but also for health care providers. If we can make it easier for patients to receive their medication, we can help maximize drug adherence or compliance,” said C. Giovanni Traverso, MB, BChir, PhD, of the Division of Gastroenterology, Hepatology and Endoscopy at the Brigham and the Department of Mechanical Engineering at MIT. “Our group focuses on developing systems that make it easier for patients to receive their medications.”
The researchers designed the L-SOMA so that it can be loaded with up to 4 mg doses of a desired medication. The pill contains a retractable needle that injects the treatment directly into tissue within the stomach. After the L-SOMA delivers the drug, the needle retracts back into the capsule. Traverso and colleagues based the L-SOMA on their initial invention, the SOMA, which injects solid medications but does not work with liquid drugs. This innovation expands upon the developed technology by enabling the device to work with liquid medications that need to be absorbed more quickly or are challenging to formulate as solids.
To evaluate the pill’s efficacy, researchers tested the L-SOMA devices in pigs, dosing each one with one of four treatments, including insulin, epinephrine, adalimumab (a monoclonal antibody used to treat rheumatoid arthritis, Crohn’s disease and other autoimmune diseases) and a semaglutide-like GLP-1 analog (an anti-diabetic medication). They then collected blood samples from each of the animals and found that the L-SOMA pill delivered medications at comparable levels to those given with an injection. They also found that repeated treatments with the L-SOMA dosed with insulin induced the same results, suggesting it may be effective to give multiple, subsequent doses using L-SOMA.
Going forward, researchers aim to test this technology in humans. They anticipate that in the future, patients may be able to orally take a diverse array of medications that were once only available via needle. Additionally, because of the L-SOMA’s injectable nature, scientists believe that it has the potential to administer vaccines, including the COVID-19 vaccine as well as potentially others. Traverso and his collaborators continue to explore what’s possible with this device.
“Through the application of fundamental engineering, the type of drugs we can deliver orally is being transformed. It changes how we think about managing different conditions,” Traverso said. “This technological advancement could apply to chronic conditions that require regular dosing or to systems that are more episodic. Mass administration of an otherwise injectable drug also becomes much easier if it can be given orally.”
Original Article: Self-injecting pill allows for oral administration of monoclonal antibodies and other injected drugs
More from: Brigham and Women’s Hospital | Massachusetts Institute of Technology
The Latest on: Self-injecting pill
- FDA Names Dupixent as the First and Only Approved Drug to Treat Eosinophilic Esophagitis (EoE)on May 24, 2022 at 9:00 pm
The U.S. Food and Drug Administration (FDA) announced the approval of Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and children ages 12 and older on May 21, 2022. The drug is ...
- Global Digital Management of Chronic Injectable Drug Patients Analysis Report 2022: Technology, Markets, Therapeutics, Strategies and Forecasts - Reseon May 19, 2022 at 9:15 am
The "Digital Management of Chronic Injectable Drug Patients" report has been added to ResearchAndMarkets.com's offering. Digital Management of Chronic Injectable Drug Patients: Technology, Markets, ...
- Injectable Drug Delivery Market Size, Share, and Global Market Forecast to 2029on May 19, 2022 at 4:07 am
The Global Injectable Drug Delivery Market is expected to grow at a high CAGR of 10.5% during the forecasting period 2022-2029 Administration of medication to manipulate winning illnesses is a ...
- A Painless, Micro Injection that You Can Do Yourself with the Latest Chula's Innovation "Detachable and Dissolvable Microneedles"on May 17, 2022 at 2:58 pm
A startup under the umbrella of CU Innovation Hub in collaboration with the Chula Faculty of Science has developed an innovative "Detachable and Dissolvable Microneedle" that makes any injections easy ...
- Injectable Drug Delivery Devices Global Market Report 2022on May 16, 2022 at 4:29 am
The increasing preference for self-injection devices is driving the injectable drug delivery devices market.Self-injection devices are medical devices that can be used by the patient in-home setting ...
- Injectable Drug Delivery Market Development, Trends, Huge Demand, Growth Analysis And Forecasts 2022-2031on May 13, 2022 at 7:26 am
Click Here To Get The Sample PDF Report: The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with ...
- Injectable Drug Delivery Market Development, Trends, Huge Demand, Growth Analysis and Forecasts 2022-2031on May 13, 2022 at 5:01 am
and Interleukin 1 (IL-1)) and improving patient compliance by the development of self-injection devices. The growth of the injectable drug delivery technologies market is primarily triggered by ...
- Officials debate drug injection siteson May 9, 2022 at 5:45 pm
‘SELF-DESTRUCTIVE BEHAVIOR ... sanctioned venues to host the injection of illegal drugs. Delaware County Sheriff Craig DuMond said allowing drug use at the sites would only facilitate addiction ...
- Self-Administration: What Drug-Delivery Device Manufacturers Should Knowon May 9, 2022 at 5:00 pm
However, even healthcare professionals carrying out injections within hospital settings ... role in ensuring the continued upward trajectory of self-administration by continually adapting their drug ...
- Proposal to allow drug injection sites in state spurs debateon May 9, 2022 at 1:58 pm
Delaware County Sheriff Craig DuMond said allowing drug use at the sites would only facilitate addiction to potentially deadly narcotics. “We would be enabling self-destructive behavior ...
via Bing News
The Latest on: Self-injecting pill
via Google News
Add Comment